Group 1 - U.S. stock futures increased, with Dow futures up approximately 200 points [1] - WhiteFiber Inc announced a $200 million Convertible Senior Notes offering, leading to a 5.5% decline in its shares to $19.19 in pre-market trading [1] Group 2 - Caleres, Inc. shares dropped 8.6% to $12.84 after naming Dan Karpel as interim CFO [2] - Aura Biosciences Inc shares fell 7% to $5.10 following a 10% gain on Wednesday [2] - GoldMining Inc shares decreased by 5.5% to $1.55 in pre-market trading [2] - T1 Energy Inc shares fell 5.4% to $7.40 after filing for a mixed shelf offering [2] - Aimei Health Technology Co Ltd shares declined 5% to $54.34 after a 22% increase on Wednesday [2] - United Microelectronics Corp shares dropped 4% to $10.69 in pre-market trading [2] - Sony Group Corp shares fell 2.8% to $23.02 in pre-market trading [2]

Group 1: High Roller Technologies Inc - High Roller Technologies Inc (NYSE:ROLR) shares increased by 29.6% to $10.21 in pre-market trading following the closure of its registered direct offering [1] - The company sold 1.89 million common shares at a price of $13.21 per share, generating approximately $25 million in gross proceeds before fees [1] Group 2: Other Stocks in Pre-Market Trading - iOThree Ltd (NASDAQ:IOTR) saw a significant gain of 80.2% to $5.28 in pre-market trading after a 12% increase on Wednesday [5] - American Rebel Holdings Inc (NASDAQ:AREB) rose 53.1% to $0.67 following the announcement of a 1-for-20 reverse stock split effective February 2 [5] - IO Biotech Inc (NASDAQ:IOBT) increased by 24.3% to $0.26 after announcing plans to explore strategic alternatives, including a merger or asset sale [5] - Moderna Inc (NASDAQ:MRNA) gained 5.5% to $52.54 after releasing five-year median follow-up data from a Phase 2b trial involving an mRNA-based neoantigen therapy [5] Group 3: Stocks Declining in Pre-Market Trading - Galaxy Payroll Group Ltd (NASDAQ:GLXG) fell 21.5% to $1.93 after a 12% decline on Wednesday [5] - Boxlight Corp (NASDAQ:BOXL) decreased by 18.7% to $1.48 after a 46% increase on Wednesday [5] - Pineapple Financial Inc (NYSE:PAPL) dropped 17% to $1.17 after a 46% jump on Wednesday following the release of first-quarter financial results [5]

Group 1 - U.S. stock futures were mostly higher, with Nasdaq 100 futures gaining around 100 points [1] - BlackBerry reported third-quarter revenue of $141.8 million, exceeding analyst estimates of $137.4 million [2] - BlackBerry's adjusted earnings were 5 cents per share, beating estimates of 4 cents per share [2] Group 2 - BlackBerry's total revenue decreased approximately 1% year-over-year, while QNX revenue grew by 10% [2] - BlackBerry shares fell 4.6% to $4.13 in pre-market trading [2] - Aimei Health Technology Co Ltd shares dropped 15.8% to $44.00 after a significant increase the previous day [3] - Nike Inc shares decreased 9.9% to $59.11 despite better-than-expected earnings and sales, due to a decline in gross margins [3] - FedEx Corp shares fell 2.2% to $281.00, despite posting strong financial results and raising FY2026 guidance [3]

Core Insights - NovaBridge Biosciences announced the appointment of Dr. Cadmus C. Rich as Chief Medical Officer and Dr. Carlos Quezada-Ruiz as Chairman of the Scientific Advisory Board for its subsidiary Visara, Inc. [1][2][3] Company Developments - The appointments of Dr. Rich and Dr. Quezada-Ruiz highlight Visara's commitment to developing innovative ophthalmic therapies, particularly the VIS-101 program targeting wet age-related macular degeneration (wet AMD) [2][5][12] - Dr. Rich aims to accelerate the development of new ophthalmology treatments and is focused on completing the Phase 2 study of VIS-101 [2][12] - Dr. Quezada-Ruiz brings extensive experience in retinal therapies and emphasizes the need for more durable treatment options for retinal diseases [2][10] Product Pipeline - VIS-101 is a bifunctional biologic targeting VEGF-A and ANG-2, with potential applications in wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO) [5][12][17] - The drug is expected to be Phase 3-ready in 2026, following the completion of its current Phase 2 study [5][12] Leadership Expertise - Dr. Rich has a strong background in ophthalmology and drug development, having previously held leadership roles in various biopharmaceutical companies [4][6][7] - Dr. Quezada-Ruiz has significant experience in the global development of retinal therapies and has held senior positions at major pharmaceutical companies [8][9][10] Strategic Vision - The appointments are part of NovaBridge's strategic transformation into a global biotech platform, showcasing its ability to attract top-tier talent in the industry [3][5] - The company aims to deliver value to shareholders through its innovative "hub-and-spoke" strategy [3]

Core Insights - NovaBridge Biosciences announced the appointment of Dr. Cadmus C. Rich as Chief Medical Officer and Dr. Carlos Quezada-Ruiz as Chairman of the Scientific Advisory Board for its subsidiary Visara, Inc. [1][2][3] Leadership Appointments - Dr. Rich and Dr. Quezada-Ruiz are recognized leaders in ophthalmology and drug development, enhancing Visara's capabilities in clinical functions and scientific advisory [2][5] - Dr. Rich aims to accelerate the development of innovative ophthalmology treatments, particularly focusing on the VIS-101 program [2][12] - Dr. Quezada-Ruiz has extensive experience in developing retinal therapies and is committed to advancing VIS-101 into registrational development [2][10] VIS-101 Program - VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, with potential applications in treating wet AMD, DME, and RVO [5][12] - The program is expected to be Phase 3-ready by 2026, following the completion of a Phase 2 study [5][12] - The dual targeting mechanism of VIS-101 is anticipated to provide more durable treatment benefits compared to current standards of care [12][18] Strategic Transformation - The appointments of Dr. Rich and Dr. Quezada-Ruiz reflect NovaBridge's strategic transformation into a global biotech platform and its commitment to delivering shareholder value [3][5] - The ability to attract distinguished leaders underscores the potential of VIS-101 and the company's innovative "hub-and-spoke" strategy [3][5] Company Overview - Visara, Inc. is focused on developing best-in-class ophthalmic therapeutics and is majority-owned by NovaBridge, which controls global rights to VIS-101 outside of Greater China [13][18] - NovaBridge is dedicated to accelerating access to innovative medicines through a combination of business development expertise and agile clinical development [15][16]